We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Brilacidin

News List

Innovation’s drug shows antiviral activity against Covid-19 in study pharmaceutical-technology
July 23, 2021
Innovation Pharmaceuticals has reported that its drug candidate, Brilacidin, showed broad-spectrum antiviral activity against Covid-19 in an in vitro study.
Innovation Pharma closes enrolment in Phase II Covid-19 drug trial pharmaceutical-technology
June 04, 2021
Innovation Pharmaceuticals has completed subject enrolment in Phase II clinical trial of its drug candidate, Brilacidin, for treating hospitalised patients with moderate-to-severe Covid-19.
Innovation Pharma to increase dosing frequency in Covid-19 drug trial pharmaceutical-technology
April 07, 2021
Innovation Pharmaceuticals is set to increase dosing frequency in Phase II clinical trial of a drug candidate, Brilacidin, for treating moderate-to-severe Covid-19 in hospitalised patients.
Innovation’s Brilacidin shows promise in-vitro against Covid-19 pharmaceutical-technology
August 26, 2020
Innovation Pharmaceuticals has reported promising data from ongoing in-vitro testing of its Brilacidin at a US Regional Biocontainment Laboratory (RBL) to treat Covid-19.